Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib Alone and in Combination in Relapsed and Refractory Leukemias
NCT03132454Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2017
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of palbociclib in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicity. Started Jul 2017; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03132454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132454.